Angina Pectoris News and Research

RSS

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.

31 Aug 2010

Study examines safety of non-invasive cardiac shock wave procedure for angina pectoris

UC San Diego Health System is enrolling a small group of patients in a two-year study to examine the safety of a non-invasive cardiac shock wave procedure for patients with chest pain caused by insufficient blood flow to the heart.

15 May 2010

Complete revascularization reduces mortality rate in CAD patients

A 3-year, retrospective study by cardiologists from the Minneapolis Heart Institute Foundation and the University of Minnesota determined that 28.8% of patients with significant coronary artery disease (CAD) who did not undergo complete revascularization had a higher mortality rate than patients completely revascularized. Results of this study appear in the May issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

24 Apr 2010

Study: 28.8% of CAD patients who fails to undergo complete revascularization face higher mortality rate

23 Apr 2010

New treatments for heart disease

Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases. The first study, carried out by a team of Brazilian researchers, found that cell transplantation of bone marrow mononuclear cells (BMMCs) directly into the heart benefited patients suffering from refractory angina.

24 Feb 2010

Italy's economically disadvantaged people have higher rates of hospitalization for ACSC disorders

Despite free public healthcare, Italy's poor are more likely to end up in hospital with avoidable conditions, new research shows. This pattern, reported today in the online open access journal BMC Public Health, mirrors findings from a number of different healthcare systems around the world, although to date fewer studies have been completed in Europe.

11 Dec 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

2 Sep 2009

Nighttime acid reflux symptoms impair sleep quality

There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Three new studies in Clinical Gastroenterology and Hepatology explore GERD's effect on sleep quality and the health-care system as well as how a widely prescribed sleeping pill may mask the disease.

1 Sep 2009

Different treatment options in chronic coronary artery disease

Sometimes cardiologists and cardiac surgeons can agree! There is often disagreement between the professions of cardiology and cardiac surgery about the proper therapy for coronary artery disease (CAD)-and this can harm the patient.

27 Apr 2009

Researchers investigate link between gastroesophageal reflux diseases and coronary heart diseases

It is well known that non-cardiac chest pain is closely related to gastroesophageal reflux diseases (GERD).

20 Apr 2009

Vulnerable plaque may be easier to detect through optical coherence tomography

Research results indicate that optical coherence tomography (OCT), a newly evolving imaging method, may be the best tool available to detect vulnerable plaque in coronary arteries. The findings will be presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

12 Oct 2008

Olmesartan may reduce coronary artery plaque

Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggests that olmesartan, a drug commonly used to treat high blood pressure, may play a role in reducing coronary plaque

12 Oct 2008

Results from the Simvastatin and Ezetimibe in aortic stenosis study

The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis.

2 Sep 2008

Do patients have equal access to coronary angiography?

Seven in ten patients who have suspected angina are not given appropriate testing and are more likely to suffer from serious heart problems as a result, according to a study published on bmj.com (25 April).

24 Apr 2008

Common drug-releasing coronary stents appear to have similar clinical outcomes

A comparison of use of the first two commercially available drug-releasing coronary stents (for the medications sirolimus and paclitaxel) among patients in "everyday clinical practice" indicates no significant differences for outcomes such as heart attack or cardiac death, according to a study in the January 30 issue of JAMA: The Journal of the American Medical Association.

30 Jan 2008

Lowering homocysteine with B-vitamins does not reduce cardiovascular risk

Secondary prevention with homocysteine-lowering B-vitamins does not reduce risk of death or major cardiovascular events, according to the WENBIT study.

3 Sep 2007